Celsius Therapeutics Names Scientific Advisers

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Celsius Therapeutics, a biotechnology company pioneering new precision medicines for patients with cancer and autoimmune disease by harnessing the power of single-cell RNA sequencing and human biology at scale, today announced the appointments of six scientific advisers.

“As Celsius prepares to advance our first programs into the clinic, we are entering a transitional point in our evolution,” said Tariq Kassum, M.D., President and CEO of Celsius. “We are thrilled to welcome this esteemed group of academic leaders – world-renowned experts in inflammatory bowel disease, oncology, immunobiology, single-cell genomics, machine learning and computational biology – to help advance our mission to bring novel precision medicines to patients with cancer and autoimmune disease.”

Celsius’ scientific advisers include:

• Maria T. Abreu, M.D. – Director, Crohn’s and Colitis Center, Professor of Medicine, and Professor of Microbiology and Immunology, University of Miami Miller School of Medicine. Dr. Abreu is an internationally recognized gastroenterologist and physician-scientist specializing in inflammatory bowel disease (IBD) with extensive clinical trial and translational medicine expertise.
• Richard Flavell, Ph.D., FRS – Sterling Professor of Immunobiology, Yale University School of Medicine; Investigator, Howard Hughes Medical Institute. A molecular biologist and immunobiology expert, Dr. Flavell’s research is fundamental to the understanding of the molecular and cellular basis of innate and adaptive immunity.
• Peter Kharchenko, Ph.D. – Principal Scientist, Altos Labs San Diego Institute; Gilbert S. Omenn Associate Professor of Biomedical Informatics, Harvard Medical School. One of the world’s leading specialists in transcriptome research and an expert in single-cell genomics, Dr. Kharchenko is focused on statistical and computational methods for analysis of high-throughput assays, with a particular focus on analysis of single-cell datasets.
• Florian Rieder, M.D. – Vice Chair, Co-director IBD Section; Director, IBD Advanced Fellowship, Department of Gastroenterology, Hepatology and Nutrition, Cleveland Clinic. A physician scientist with extensive clinical research experience, Dr. Rieder is internationally recognized for his clinical and translational expertise in IBD and has been instrumental in developing clinical guidelines in ulcerative colitis and Crohn’s Disease for the European Crohn’s and Colitis Organization (ECCO).
• Ton Schumacher, Ph.D. – Senior Member, The Netherlands Cancer Institute; Venture Partner, Third Rock Ventures. A cancer immunology expert, Dr. Schumacher has taken an engineering-based approach to dissect cancer-specific immunity and is internationally recognized for his work to reveal the mechanisms behind T cell recognition of cancer.
• Nir Yosef, Ph.D. – Associate Professor, Department of Systems Immunology, the Weizmann Institute; Associate Professor, Department of Electrical Engineering and Computer Science, University of California, Berkeley. A computational biologist and expert in single-cell genomics, Dr. Yosef’s research focuses on developing and applying computational tools that leverage single-cell genomics, with the goal of better understanding the factors that contribute to variability between immune cells.

About Celsius Therapeutics

Celsius Therapeutics is a biotechnology company developing novel precision medicines in autoimmune disease and cancer by harnessing the power of single cell RNA sequencing and human biology at scale. The company’s first therapeutic candidate is an anti-TREM1 antibody for the treatment of inflammatory bowel disease, and the company has multiple ongoing drug discovery programs in oncology. Celsius is based in Cambridge, Mass. For more information, please visit www.celsiustx.com, or follow us on LinkedIn or Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220922005061/en/